IRIS
ROGLIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 71.876
EU - Europa 5.891
AS - Asia 4.175
SA - Sud America 83
OC - Oceania 30
AF - Africa 23
Continente sconosciuto - Info sul continente non disponibili 22
Totale 82.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 71.811
SG - Singapore 1.965
CN - Cina 1.150
IE - Irlanda 1.055
IT - Italia 969
UA - Ucraina 781
KR - Corea 742
DE - Germania 693
RU - Federazione Russa 564
PL - Polonia 465
FR - Francia 437
GB - Regno Unito 299
FI - Finlandia 215
SE - Svezia 205
ID - Indonesia 74
CA - Canada 55
NL - Olanda 49
BR - Brasile 44
VN - Vietnam 42
JP - Giappone 38
BE - Belgio 35
IN - India 31
ES - Italia 27
AU - Australia 25
HK - Hong Kong 24
RO - Romania 16
CL - Cile 14
CZ - Repubblica Ceca 14
GR - Grecia 14
MY - Malesia 13
A2 - ???statistics.table.value.countryCode.A2??? 11
PH - Filippine 11
TR - Turchia 11
EU - Europa 10
TW - Taiwan 10
EC - Ecuador 9
IL - Israele 9
PT - Portogallo 9
AT - Austria 7
EG - Egitto 7
KG - Kirghizistan 7
CO - Colombia 6
IR - Iran 6
MX - Messico 6
HR - Croazia 5
NZ - Nuova Zelanda 5
PE - Perù 5
RS - Serbia 5
AR - Argentina 4
CH - Svizzera 4
DK - Danimarca 4
IQ - Iraq 4
LY - Libia 4
PK - Pakistan 4
UZ - Uzbekistan 4
BD - Bangladesh 3
ET - Etiopia 3
JO - Giordania 3
KE - Kenya 3
KH - Cambogia 3
KZ - Kazakistan 3
NP - Nepal 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CR - Costa Rica 2
EE - Estonia 2
HU - Ungheria 2
IS - Islanda 2
LK - Sri Lanka 2
LT - Lituania 2
LV - Lettonia 2
MK - Macedonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NG - Nigeria 2
NO - Norvegia 2
TH - Thailandia 2
ZA - Sudafrica 2
A1 - Anonimo 1
AM - Armenia 1
AZ - Azerbaigian 1
GT - Guatemala 1
LB - Libano 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
NI - Nicaragua 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
VE - Venezuela 1
Totale 82.100
Salva come PNG Salva come JPEG
Città #
Wilmington 19.935
Houston 18.432
Woodbridge 18.204
Fairfield 2.959
Singapore 1.713
Ann Arbor 1.452
Chandler 1.247
Ashburn 1.236
Seattle 1.173
Cambridge 955
Dublin 902
Medford 685
Jacksonville 558
Dearborn 461
Kraków 456
Santa Clara 421
Beijing 362
New York 359
Rome 339
Lawrence 321
Zhengzhou 279
San Diego 173
Menlo Park 106
Moscow 106
Milan 84
Hangzhou 73
Shanghai 73
Jakarta 68
Redwood City 63
Norwalk 62
London 58
Palo Alto 46
Helsinki 45
Jinan 42
Nanjing 40
Mülheim 37
Dong Ket 35
Boardman 33
Brussels 33
Hefei 33
Guangzhou 28
Mountain View 28
San Jose 28
Falls Church 27
Verona 26
Kunming 25
La Veta 25
Los Angeles 25
Phoenix 25
Chicago 23
Seoul 23
Toronto 22
Detroit 21
Durham 21
Lappeenranta 21
San Francisco 19
Saint Petersburg 17
Naples 16
Council Bluffs 15
Kilburn 15
Nuremberg 15
Chengdu 14
São Paulo 14
Jiaxing 13
Munich 13
Nanchang 13
Parma 13
San Mateo 13
Wuhan 13
University Park 12
Prescot 11
Redmond 11
Hounslow 10
Washington 10
Brno 9
Kuala Lumpur 9
Stockholm 9
Amsterdam 8
Central 8
Frankfurt am Main 8
Fuzhou 8
Hong Kong 8
Acton 7
Athens 7
Bari 7
Chiswick 7
Indianapolis 7
Manila 7
Melbourne 7
The Dalles 7
Tokyo 7
Xi'an 7
Canberra 6
Giv‘atayim 6
Iasi 6
Islington 6
Leeds 6
Palermo 6
Quito 6
Shenyang 6
Totale 74.469
Salva come PNG Salva come JPEG
Nome #
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 493
An update on the pharmacotherapeutic management of lower respiratory tract infections 493
Vats lung reduction in patients with advanced emphysema 490
Thoracoscopic reduction pneumoplasty for severe emphysema: Do pleural adhesions affect outcome? 469
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 464
Awake thoracoscopic biopsy of interstitial lung disease 463
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 462
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 461
Effect of lung volume reduction surgery for severe emphysema on right ventricular function 454
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 454
Interaction between corticosteroids and muscarinic antagonists in human airways 453
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 447
Completion lobectomy after bilateral lung volume reduction for emphysema: Salvage option or fancy? 445
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 441
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 437
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 437
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 437
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 436
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 431
Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma 431
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 429
Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema 426
Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors 426
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 426
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 423
Optimizing drug delivery in COPD: The role of inhaler devices 423
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 422
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 422
Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase 421
Asthma and comorbid medical illness. 419
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 419
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 419
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 418
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis 418
Tiotropium formulations and safety: a network meta-analysis 417
Airflow obstruction: Is it asthma or is it COPD? 416
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 416
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 414
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? 414
Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? 412
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? 412
Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. 411
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 410
How many systemic reactions to skin prick tests could be preventable in defined conditions? 408
Occupational allergy to horse allergens: More than exposure to horses! 407
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 407
Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in “real life”? 407
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 406
Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy? 406
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 405
Asthma and comorbid medical illness 404
Role of muscarinic antagonists in asthma therapy 404
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 402
Occupational allergy to horse allergens: More than exposure to horses! 402
Bronchodilator therapy for chronic cough 402
The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators 400
Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement 399
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 399
Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity 397
Dog allergen immunotherapy and allergy to furry animals 396
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey 396
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 395
Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs 394
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 393
Metabolic syndrome and risk of pulmonary involvement 392
Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. 392
The Challenges of Precision Medicine in COPD 392
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 391
HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema 390
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 390
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 388
New Treatments for COPD in the Elderly 388
Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies 388
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 387
Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis 386
Umeclidinium for the treatment of chronic obstructive pulmonary disease 385
Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract 385
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 385
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 384
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 383
The effect of indacaterol during an acute exacerbation of COPD 383
Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience 382
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 382
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 380
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 378
Translational study searching for synergy between glycopyrronium and indacaterol 376
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 376
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 376
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 375
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 375
Comorbidities of asthma 375
Impact of pulmonary vascular volume on mortality in IPF: Is it time to reconsider the role of vasculature in disease pathogenesis and progression? 375
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 374
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 373
Biomarkers of lung damage associated with tobacco smoke in induced sputum 372
HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells 372
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 372
Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure 372
Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? 371
Influence of ethnicity on response to asthma drugs 370
Totale 40.875
Salva come PNG Salva come JPEG
Categoria #
all - tutte 195.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 195.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013.644 0 0 0 0 0 2.548 2.110 2.160 2.138 1.787 1.395 1.506
2020/202113.581 1.435 1.552 1.496 1.545 1.381 1.405 2.056 1.300 353 361 485 212
2021/20223.251 200 278 87 72 105 323 424 149 182 304 280 847
2022/20233.580 469 253 122 398 280 912 325 209 320 36 164 92
2023/20241.812 362 47 133 38 129 392 110 200 60 71 36 234
2024/20254.261 298 1.974 995 483 318 193 0 0 0 0 0 0
Totale 83.471